Comparing oxazaphosphorines for treating Ewing sarcoma: is the answer important two decades later?

Affiliations

¹ University of Oklahoma Health Sciences Center, Oklahoma City, OK william-meyer@ouhsc.edu.
² Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.

Editorial

William H Meyer et al. J Clin Oncol. 2014.

. 2014 Aug 10;32(23):2401-2.

doi: 10.1200/JCO.2014.56.3379. Epub 2014 Jun 30.

¹ University of Oklahoma Health Sciences Center, Oklahoma City, OK william-meyer@ouhsc.edu.
² Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.

No abstract available

Comment on

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Bérard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8. doi: 10.1200/JCO.2013.54.4833. Epub 2014 Jun 30. J Clin Oncol. 2014. PMID: 24982464 Clinical Trial.